Merck’s 3Q Revenues up 4%

Merck
3Q Revenues: $16.7 billion (+4%)
3Q Earnings: $3.15 billion (-33%)
YTD Revenues: $48.5 billion (+7%)
YTD Earnings: $13.4 billion (earnings were $1.6 billion YTD23)
Comments: KEYTRUDA sales were up 17% to $7.4 billion in the quarter. Newly launched WINREVAIR to treat Pulmonary Arterial Hypertension had sales of $149 million. Gardasil sales were down 10% to $2.3 billion primarily due to lower demand in China, partially offset by higher sales in the U.S. Januvia sales were down 38% to $482 million, due to lower pricing in the U.S., as well as ongoing generic competition. Bridion sales were flat at $420 million. Covid-19 drug Lagevrio sales were down 36% to $383 million due to lower demand in Japan, partially offset by uptake from commercial launch in the U.S. Lynparza sales were up 13% to $337 million. Earnings in the quarter were impacted by the acquisition of Eyebiotech and a related development milestone.